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Analysis of transition state mimicry by tight binding
aminothiazoline inhibitors provides insight into
catalysis by human O-GlcNAcase†
N. Cekic,‡a J. E. Heinonen,‡a K. A. Stubbs,ab C. Roth,c Y. He,c A. J. Bennet,a
E. J. McEachern,§a G. J. Daviesc and D. J. Vocadlo*ad
The modiﬁcation of nucleocytoplasmic proteins with O-linked N-acetylglucosamine (O-GlcNAc) plays
diverse roles in multicellular organisms. Inhibitors of O-GlcNAc hydrolase (OGA), the enzyme that
removes O-GlcNAc from proteins, lead to increased O-GlcNAc levels in cells and are seeing widespread
adoption in the ﬁeld as a research tool used in cells and in vivo. Here we synthesize and study a series of
tight binding carbohydrate-based inhibitors of human OGA (hOGA). The most potent of these
20-aminothiazolines binds with a sub-nanomolar Ki value to hOGA (510  50 pM) and the most selective
has greater than 1 800 000-fold selectivity for hOGA over mechanistically related human lysosomal
b-hexosaminidase. Structural data of inhibitors in complex with an hOGA homologue reveals the basis
for variation in binding among these compounds. Using linear free energy analyses, we show binding of
these 20-aminothiazoline inhibitors depends on the pKa of the aminothiazoline ring system, revealing the
protonation state of the inhibitor is a key driver of binding. Using series of inhibitors and synthetic
substrates, we show that 20-aminothiazoline inhibitors are transition state analogues of hOGA that bind
to the enzyme up to 1-million fold more tightly than the substrate. These collective data support an
oxazoline, rather than a protonated oxazolinium ion, intermediate being formed along the reaction
pathway. Inhibitors from this series will prove generally useful tools for the study of O-GlcNAc. The new
insights gained here, into the catalytic mechanism of hOGA and the fundamental drivers of potency and
selectivity of OGA inhibitors, should enable tuning of hOGA inhibitors with desirable properties.
Introduction
The modication of serine and threonine residues of nuclear
and cytoplasmic proteins with terminal O-linked b-N-acetyl-
glucosamine (O-GlcNAc)1 has been found on hundreds of
proteins.2–4 O-GlcNAc is present in all multi-cellular eukaryotes
studied and occurs in a dynamic and reversible manner.5Global
O-GlcNAc levels have been shown to vary in response to cellular
nutrient availability and stress and in some cases has been
found to inuence protein phosphorylation.6 These observa-
tions have stimulated interest in the physiological roles played
by O-GlcNAc and research has implicated this modication in
controlling various cellular processes including, for example,
proteosomal degradation of proteins7–9 and transcriptional
regulation.10,11 Additionally, a growing body of literature has
implicated O-GlcNAcylation in chronic diseases such as neu-
rodegeneration12–15 and cancer.9,16,17 Given the mounting
potential in targeting protein O-GlcNAcylation for therapeutic
benet, there has been rising interest in understanding the
molecular basis for inhibition of modulators of the O-GlcNAc
pathway and the creation of small molecule modulators of this
pathway for use in tissues.18–20
The glycosyltransferase uridine diphospho-N-acetylglucosami-
ne:peptide b-N-acetylglucosaminyl transferase (OGT) installs O-
GlcNAc residues using uridine diphosphate N-acetylglucosamine
(UDP-GlcNAc) as the sugar substrate donor.21,22 The enzyme
responsible for removing O-GlcNAc from proteins is O-GlcNAcase
(OGA),23 which is a member of glycoside hydrolase family 84
(GH84) of the CAZy classication system.24 Consistent with
the reversible nature of protein O-GlcNAcylation, inhibitors
of these enzymes have been shown to induce time-dependent
changes in cellular O-GlcNAc levels.19,25–27 Small molecule
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inhibitors of OGA, in particular, have emerged as commonly used
research tools for evaluating the phenotypic eﬀects of increasedO-
GlcNAc levels in cultured cells, as well as in vivo.
Interest in inhibitors of OGA has gained increasing atten-
tion due to growing recognition of the physiological roles of
O-GlcNAc. Among the rst reported inhibitors of OGA is
O-(2-acetamido-2-deoxy-D-gluco-pyranosylidene)amino-N-phe-
nylcarbamate (PUGNAc, Fig. 1, 1)28 (hOGA Ki ¼ 46 nM). This
inhibitor, however, has well-described oﬀ target eﬀects29,30
including the inhibition of the functionally related lysosomal
b-hexosaminidases HEXA and HEXB from family GH20.26
These two lysosomal enzymes cleave b-linked terminal N-ace-
tylhexosamine residues from various glycoconjugates
including gangliosides. Genetic deciency of these hexosa-
minidases results in Tay–Sachs and Sandhoﬀ's disease,
which stem from the accumulation of gangliosides within
lysosomes. More recently identied inhibitors such as 6-acet-
amido-6-deoxy-castanospermine (6-Ac-Cas)29 (hOGA Ki¼ 300 nM)
(Fig. 1, 2), and 1,2-dideoxy-20-methyl-a-D-glucopyranoso-[2,1-d]-
D20-thiazoline (NAG-thiazoline)26 (hOGA Ki ¼ 70 nM) (Fig. 1, 3)
while fairly potent, are also non-selective. Given that gangliosides
play varied roles in cellular processes ranging from cell
membrane structure to cell signaling, the selectivity of OGA
inhibitors has emerged as being important for the creation of
useful probe molecules for use in vivo.29,31,32
Rationally designed OGA inhibitors have been pursued
based on knowledge of the catalytic mechanism of hOGA.
Detailed mechanistic studies26,33 coupled with structural studies
of bacterial homologues of hOGA34,35 have provided clear
support for a catalytic mechanism involving substrate-assisted
catalysis in which the 2-acetamido group of the substrate serves
as a catalytic nucleophile to generate a transient enzyme-bound
oxazoline or oxazolinium intermediate (Fig. 1A) and stabilizing
an oxocarbenium ion-like transition state (Fig. 1B). In this two-
step catalytic mechanism, two aspartates (Asp174 and Asp175)
play key roles as general acid/base catalytic residues.33 Asp174
serves to orient and polarize the 2-acetamido group to aid its
attack at the anomeric center, accepting a proton during
formation of the oxazoline ring. Asp175 acts as a general acid,
donating a proton to the glycosidic oxygen during cleavage of
the glycosidic bond (Fig. 1A and B). Given the clear resemblance
of NAG-thiazoline to the oxazoline intermediate, analogues of
this molecule in which the 20-position of the thiazoline ring is
modied showed fair selectivities coupled with moderate
nanomolar potencies as exemplied by NButGT (hOGA Ki¼ 230
nM, Ki(HEX)/Ki(hOGA) ¼ 1,500, Fig. 1C, 4).
26
More selective hOGA inhibitors have since been generated
including the GlcNAcstatins27,36 such as GlcNAcstatin C (hOGA Ki¼
3.2 nM, Ki(HEX)/Ki(hOGA)¼ 190) and a bioisostere of NButGT, 1,2-
dideoxy-20-ethylamino-a-D-glucopyranoso-[2,1-d]-D20-thiazoline
(ThiamEt-G)(hOGA Ki ¼ 21 nM, Ki(HEX)/Ki(hOGA) ¼ 37 000)
19
(Fig. 1C, 5), which is more synthetically accessible. ThiamEt-G is
orally available and increases brain O-GlcNAc levels in mammals
and has been used by several groups to show chronic OGA
inhibition and increased O-GlcNAcylation over several months
has no apparent deleterious eﬀects and also protects in various
mouse models of AD against both tau14,37,38 and amyloid
pathologies.39,40 Given the great interest in OGA inhibitors as
research tools, we aimed to explore the basis for the inhibition
of hOGA by ThiamEt-G. Here we report on the synthesis and
characterization of aminothiazoline inhibitors with hOGA and
human HexB (hHexB), demonstrate the strongly pKa dependent
inhibition of hOGA by such inhibitors, illuminate the molecular
basis for observed selectivity and potency using structural
biology, and reveal these inhibitors are genuine TS analogues –
which reveals new insight into the nature of the catalytic
mechanism as well as explaining the picomolar binding of the
best representative from this inhibitor family.
Fig. 1 Catalytic mechanism of OGA and lysosomal b-hexosaminidases and some known hOGA inhibitors. (A) hOGA uses a substrate-assisted
catalytic mechanism involving two key catalytic aspartate residues that enable the transient formation of an oxazoline intermediate. R ¼ leaving
group. (B) The proposed transition state (TS) for formation of the oxazoline intermediate. Note that the extent of proton transfer to the stabilizing
residue D174/D354 is not known. (C) Some known hOGA inhibitors. Catalytic residues are D174/D175 for human OGA and D354/E355 for human
lysosomal b-hexosaminidase A.
This journal is © The Royal Society of Chemistry 2016 Chem. Sci., 2016, 7, 3742–3750 | 3743
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Results and discussion
Early studies showed that varying the 20-alkyl substituent of
NAG-thiazoline resulted in increased selectivity for OGA over
the lysosomal hexosaminidases at the slight expense of
potency.26 This trend does not hold for PUGNAc analogues
which show only modest selectivity.41,42 Exploiting a similar
approach of increasing steric bulk of the acetamido group,
however, cell-penetrant glucoimidazole inhibitors including the
hOGA inhibitors GlcNAcstatin G (hOGA ¼ 4.1 nM, Ki(HEX)/
Ki(hOGA) ¼ 900 000) (Fig. 1C, 6) and GlcNAcstatin H (hOGA ¼
2.6 nM, Ki(HEX)/Ki(hOGA) ¼ 35 000) (Fig. 1C, 7), have been
uncovered as some of the most selective hOGA inhibitors to
date.20 Structural studies have suggested that these OGA
inhibitors derive their selectivity from structural diﬀerences
between the active sites of OGA and the lysosomal b-hexosa-
minidases in the region that serves to position the 2-acetamido
group of the substrate.34,43 We therefore rst set out to gain an
understanding of the detailed relationships between the size of
substituents at the 20-position of a series of 20-aminothiazoline
inhibitors and the inuence on binding of altered electronic
properties of the 20-aminothiazoline system.
Preparation, potency, and selectivity of 20-
alkylaminothiazoline OGA inhibitors
Using three diﬀerent approaches (Scheme 1) we synthesized
a series of 20-alkylaminothiazoline derivatives. Using the common
intermediate hydrochloride salt of 1,3,4,6-tetra-O-acetyl-2-amino-
2-deoxy-b-D-glucopyranose 8 (Scheme 1A and B), which was
conveniently accessed in three steps,44 we prepared compounds
11a and 11b by reacting either N-uorenylmethyloxycarbonyl
(Fmoc)-protected isothiocyanate orN-allyl isothiocyanate with 8 in
the presence of triethylamine to generate the respective thiourea
intermediates 9a and 9b. Subsequent cyclization with excess SnCl4
followed by a two step deprotection using catalytic NaOMe in
anhydrous methanol, and piperidine catalyzed removal of the
Fmoc group, aﬀorded analogue 11a. Cyclization of thiourea 9b
with excess TFA, followed by a one step deprotection using cata-
lytic K2CO3 in anhydrous methanol aﬀorded inhibitor 11b.
Inhibitors 15a–h were synthesized using an alternate route
from the common isothiocyanate intermediate 1,3,4,6-tetra-O-
acetyl-2-deoxy-2-isothiocyanato-b-D-glucopyranose (Scheme 1C,
12), which was prepared from 8 via a biphasic reaction in H2O/
DCM with thiophosgene.44 Reaction of isothiocyanate 12 with
a series of alkylamines and dialkylamines, or their respective
hydrochloride salts, yielded thioureas 13a–h. Acid catalyzed
cyclization of these thiourea-containing compounds using TFA
provided protected aminothiazolines 14a–h, which aer
deprotection with K2CO3 aﬀorded 15a–h.
We then determined the Ki values for inhibition of hOGA by
compounds 11a–b and 15a–h. Using Michael–Menten kinetics
we obtained the Ki values for the less potent inhibitors 15e–h,
and as expected, double-reciprocal Lineweaver–Burk plots
revealing a competitive mode of inhibition (ESI Fig. S1†). For
the increasingly tight binding inhibitors we used the non-linear
tting method described by Morrison,45 which can be used to
determine Ki values which are comparable to the concentration
of the enzyme being studied. Renement of the Morrison
approach by Copeland enables dening the Ki value for an
inhibitor through the use of relative rates using a quadratic
equation (eqn (1)).46 This approach depends on knowing the
initial free enzyme and inhibitor concentrations without the
Scheme 1 Synthesis of OGA inhibitors 11a–b and 15a–h from 8 and 12, respectively. (A) 11a: (a) 1. NEt3, DCM; 2. Fmoc-NCS, pyridine, NEt3; (b)
SnCl4, pyridine, NEt3; (c) 1. (i) NaOMe, MeOH; (ii) AcOH; 2. piperidine, DMF; (B) 11b: (d) allyl-NCS (2 eq.), NEt3 (2 eq.), CH3CN; (e) TFA (7.5 eq.),
DCM; (f) K2CO3, MeOH; (C) 15a–h: (g) NHR1R2$HCl (1.2 eq.), NEt3 (1.2 eq.), CH3CN; (h) TFA (7.5 eq.), DCM (i) K2CO3, MeOH; 13a–15a: R1¼H, R2¼
CH3; 13b–15b: R1 ¼ CH3, R2 ¼ CH3; 13c–15c: R1 ¼ H, R2 ¼ CH2CH3; 13d–15d: R1 ¼ H, R2 ¼ (CH2)2CH3; 13e–15e: R1 ¼ H, R2 ¼ (CH2)3CH3; 13f–
15f: R1 ¼ H, R2 ¼ (CH2)2F; 13g–15g: R1 ¼ H, R2 ¼ CH2CHF2; 13h–15h: R1 ¼ H, R2 ¼ CH2CF3.
3744 | Chem. Sci., 2016, 7, 3742–3750 This journal is © The Royal Society of Chemistry 2016
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assumption that the free inhibitor concentration is equal to the
total inhibitor concentration.
vi ¼
v0 1

½ET þ ½IT þ K
app
i


ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
½ET þ ½IT þ K
app
i
2
 4½ET½IT
q
2½ET
2
4
3
5
(1)
Further, Ki values can be accurately determined over a wide
range of enzyme concentrations using this method,47 which
enabled us to use hOGA concentrations that permit accurate
initial rate determinations. We followed existing guidance48 to
select inhibitor concentrations for our Ki value determinations
and conrmed the accuracy of this method by showing the Ki
values for inhibitor 11b were in reasonable accord when using
either the Michaelis–Menten or Morrison method (ESI Fig. S2†).
Using these methods we found the Ki values for inhibition of
hOGA by compounds 11a–b and 15a–h ranged from the high
sub-nanomolar to low nanomolar range (Table 1). Notably, we
nd that the Ki value for ThiamEt-G (Fig. 1 and 2) was 10-fold
lower (Ki ¼ 2.1 nM) than that previously determined
19 using the
Michaelis–Menten method (Ki¼ 21 nM). This makes Thiamet-G
over 100-fold more potent than the isosteric NButGT (Ki ¼
230 nM). The most tight-binding compound with a Ki of 510 
50 pM (Fig. 2) is 15a (ThiamMe-G, Scheme 1), which ranks this
compound among the most potent glycoside hydrolase inhibi-
tors known, as well as the most potent selective hOGA inhibitor
reported. Interestingly, we note that there is only a slight
decrease in potency for hOGA upon increasing the volume of
the 20-aminoalkyl substituent to the point where the alkyl group
is a propyl (15d, Ki ¼ 2 nM). A butyl chain, however, leads to
a greater than 100-fold loss of potency (15e, Ki ¼ 350 nM).
Structures of bacterial OGA homologues, in which the active site
residues are completely conserved with hOGA,34,35 show
a discretely sized pocket having a volume that nicely accom-
modates the propyl substituent of 15d.
To assess the structural basis for this stepped decrease in
potency observed on going to the 20-aminobutylthiazoline 15e, we
determined the structure of Bacteroides thetaiotaomicron,
a bacterial homolog (BtGH84) of hOGA, in complex with the
parent 20-aminothiazoline 11a, the tighter binding 20-amino-
propylenethiazoline 11b, and the butyl derivative 15e, which
shows greatly diminished binding. In all three structures, the
respective inhibitor binds in the active site in a conserved mode
with an invariant hydrogen bond pattern for the aminothiazoline
moiety (Fig. 3). The alkyl chain of the modied aminothiazolines
points into the conserved hydrophobic pocket as shown for
ThiamEt-G.19 An inspection of the binding pocket shows no
further hydrophobic interactions in the case of the unsubstituted
aminothiazoline 11a, except a possible weak electrostatic inter-
action with C278 at the bottom of the pocket (Fig. 3A). Propylene
derivative 11b matches the size of the pocket, requiring only
a minor adjustment of the C278 rotamer and showing favorable
hydrophobic interactions with W337, T310, and Y282 (Fig. 3B).
Even a small further extension of the alkyl chain, as in the butyl
derivative 15e, leads to steric clashes with multiple residues in
the cavity, driving the side chain of C278 to adopt a diﬀerent
orientation. Furthermore, we observe the polypeptidemain chain
surrounding C278 is shied away from the inhibitor. Thus, the
size of the pocket disfavors substituents longer than three carbon
units in chain length, and those inhibitors having such larger
groups induce unfavorable conformational changes within the
active site (Fig. 3C and D).
We next set out to assess the selectivity of this series of
inhibitors for hOGA over the lysosomal b-hexosaminidases,
which are comprised of combinations of a and b subunits that
are products of the highly homologous HEXA and HEXB genes.
Using puried human hexosaminidase B (hHexB) we deter-
mined the approximate Ki values for compounds 11a to 15h
using Dixon plot analysis and found remarkably high inhibitor
selectivities ranging from 1100- to 1 850 000-fold preference for
hOGA (Table 1). We conrmed these Dixon plot analyses for the
two most potent compounds, 11a and 15a, by determining full
Ki values for their inhibition of hHexB (ESI Fig. S4†). Remark-
ably, inhibitors 11a and 15a still retain 1100 and 3300-fold
selectivity for hOGA despite their similarity in size to
NAG-thiazoline, which itself demonstrated no selectivity.26
Accordingly, the presence of the 20-amino substituent, on its
own, confers at least 1000-fold selectivity for hOGA over hHexB.
Table 1 Ki selectivity ratios of inhibitors 11a to 15h for hOGA over hHexB and the pKa values for 15c, 15f–h
Inhibitor hOGA Ki
a (nM) hHexB Ki
b (mM) (hHexB/hOGA)c pKa
e Fraction protonated at pH 7.4
11a: R1 ¼ R2 ¼ H 4.7  0.3 5.0  0.6
d 1100
15a: R1 ¼ H, R2 ¼ CH3 0.51  0.05 1.7  0.19
d 3300
15b: R1 ¼ R2 ¼ CH3 2.4  0.2 13.0  3.8 5400
15c: R1 ¼ H, R2 ¼ CH2CH3 2.1  0.3 740  60 (ref. 19) 350 000 7.68 0.66
11b: R1 ¼ H, R2 ¼ CH2CHCH2 3.2  0.4 2850  570 950 000
15d: R1 ¼ H, R2¼ (CH2)2CH3 2.0  0.2 3700  670 1 850 000
15e: R1 ¼ H, R2¼ (CH2)3CH3 350  90
d 4800  763 13 700
15f: R1 ¼ H, R2¼ (CH2)2F 15  5
d 180  44 12 000 6.92 0.25
15g: R1 ¼ H, R2 ¼ CH2CHF2 60  10
d 150  50 2500 6.18 0.06
15h: R1 ¼ H, R2 ¼ CH2CF3 1000  200
d 4200  1525 4200 5.33 0.01
a Determined using the Morrison Ki t if the values are below 5 mM.
b Determined using Dixon plot analysis. c Selectivity ratios representing the
favored selectivity for hOGA compared to hHexB. d Determined using Michaelis–Menten inhibition analysis. e See ESI for full details, pKa (NButGT)
¼ 4.65.
This journal is © The Royal Society of Chemistry 2016 Chem. Sci., 2016, 7, 3742–3750 | 3745
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We also noted that the selectivity ratio for hOGA increases as
the 20-aminoalkyl chain length increases to the three-carbon
propyl (15d) and propylene (11b) derivatives, but this trend
reverses once the chain length increases further, as seen for the
20-aminobutyl analogue (15e). Since the active site pocket for
hHexB is more constrained in the vicinity of the acetamido
group, these observations are consistent with structural obser-
vations of both bacterial hOGA homologues34 and hHexB.43 This
suggests that once the 20-substituent passes the volume that can
be accommodated in the active site of hOGA, increases in bulk
are even slightly more deleterious for hOGA as compared to
hHexB.
Preparation of 20-alkylaminothiazoline OGA inhibitors for
evaluating electronic eﬀects in OGA inhibition
Notably, ThiamEt-G (Ki ¼ 2.1 nM) binds over 100-fold more
tightly than NButGT (Ki ¼ 230 nM) and is 25-fold more selective
for hOGA. Detailed mechanistic studies in combination with
pH-rate proles of wild-type and mutant hOGA revealed the key
catalytic residue Asp174 in the OGA catalytic site (Asp242 in
BtGH84) acts as a general base to assist the attack of the
substrate 2-acetamido group onto the anomeric center. The
kinetic pKa of this residue was determined to be 5.2 so that at
physiological pH this residue is expected to be in its carboxylate
form33 and therefore suitably ionized in the resting enzyme to
facilitate catalysis. Given that aminothiazolines are known to be
more basic than thiazolines, it was speculated that installation
of the 20-alkylamino group would increase the basicity of Thia-
mEt-G as compared to NButGT and thereby contribute to its
enhanced potency relative to inhibitors bearing 20-alkyl groups
at physiological pH. Structural data of ThiamEt-G bound within
the active site of BtGH84 is consistent with this proposal,
revealing that both the endo and exocyclic amines engaged
Asp242 of BtGH84.19
We set out to evaluate this proposal and assess the impor-
tance of the inhibitor pKa on potency by studying a series of 2
0-
aminoethylthiazoline inhibitors with increasing uorine
substitution at the terminal methyl group (15f–h). Evaluation of
the potency of these compounds revealed a progressive increase
in Ki value upon increasing substitution with uorine [Ki ¼ 2.1
(CH3, 15c) 15 (CH2F, 15f), 60 (CHF2, 15g) and 1000 (CF3, 15h)
nM] (Table 1). To clearly understand the relationship between
inhibitor basicity and potency we used 13C NMR titration to
determine the pKa values of conjugate acids of these inhibitors
(15c, 15f–h). NMR methods are highly accurate and can be used
to determine relative pKa values between one or more
compounds having an unknown pKa and a reference compound
having a well established pKa value.
49
Practically, two advantages of this relative measurement
approach is that it does not require repeated pH measurements
throughout the titration and it can be used to evaluate small
changes in pKa values. In this way, a non-linear plot of the
diﬀerence between NMR resonance frequencies for
a compound of interest and those for a standard, such as
3-nitrophenol, can be used to determine the ratio (R) of the acid
Fig. 2 Representative Morrison data and ﬁtted curves used to obtain Ki values for the tight binding hOGA inhibitors, shown for ThiamMe-G (15a)
and ThiamEt-G (15c). Data was obtained in triplicate and error bars represent the standard error of the mean (S.E.M.).
Fig. 3 Cartoon plots of BtGH84 in complex with 11a (A), 11b (B) and
15e (C). The inhibitors are shown in stick representation. The side
chains of the residues forming the active site are shown in stick
representation. Hydrogen bonds between the protein and the inhibitor
are shown as black dashed lines. Close contacts (d < 3.4 A˚) of buty-
laminothiazoline (C) are shown as red dashed lines. (D) shows an
overlay of all three structures based on the bound aminothiazoline.
The respective protein environment is coloured in darkblue for ami-
nothiazoline containing structure, for propyleneaminothiazoline in
bluegreen and butylaminothiazoline in beige. A change of the rotamer
of C278 and a shift of the corresponding b-strand is observed in
response to the steric repulsion with the butyl substituent.
3746 | Chem. Sci., 2016, 7, 3742–3750 This journal is © The Royal Society of Chemistry 2016
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dissociation constants between these two materials. A typical
plot for the diﬀerence in 13C chemical shis is shown in Fig. 4
(see ESI† methods for a full discussion).
To assess the extent to which inhibitor potency depends on
its pKa value, we plotted the pKa value of inhibitors (15c, 15f–h
and NButGT, 4) with the corresponding log Ki, which are both
free energy terms. The resulting linear free energy relationship
(LFER) shows a linear correlation (R2 ¼ 0.9876) with a slope of
1.12  0.09 (Fig. 5), which is consistent with the pKa value of
inhibitors mostly dominating the eﬀect of binding as compared
to steric eﬀects associated with increasing uorine substitution.
Notably, we also nd that NButGT, which is isosteric to Thia-
mEt-G (15c), matches reasonably well within this correlation,
supporting the electronic eﬀects dominating this correlation.
While the aﬃnities of each protonation state of these inhibitors
for hOGA (Fig. 5) cannot be readily determined because the
enzyme itself has various ionization states, these data collec-
tively suggest that the pKa value of the inhibitor, either by
favoring the protonated inhibitor form or by optimizing
hydrogen bonding strength, plays a key role in binding of these
20-aminothiazoline inhibitors.
Assessment of 20-aminothiazoline inhibitors as transition
state analogs
The tight binding of these 20-aminothiazoline inhibitors
prompted us to consider their potency in the context of their size.
One widely used parameter to understand the eﬃciency of
binding as a function of molecular weight is to consider the
ligand eﬃciency (LE) of a ligand. This measure provides the
binding aﬃnity of the compound as a measure of the number of
heavy atoms. We calculate a remarkably high LE of 0.88 kcal per
mol per heavy atom for compound 15a. Such a LE is comparable
to some of the highest ever observed LEs observed for
compounds in the size range of between 10–50 heavy atoms50 and
suggests to us that these compounds could well be TS analogues,
as had been observed for the related thiazoline inhibitors51.
Tight-binding inhibitors that bear resemblance to enzyme
substrates or intermediates have oen been considered to be TS
analogues simply by virtue of their potency. However, because
enzymes are thought to catalyze reactions by tightly binding the
TS, for genuine TS analogues changes in free energies of binding
of a series of TS analogues (log Ki) should parallel changes in
the free energies of a series of related transition states TS
(log kcat/Km). Bartlett has formalized these concepts andmethods
to quantitatively assess whether compounds are TS analogues
using LFERs.52,53 Using this method, genuine TS analogues yield
plots of log Km/kcat values, for a series of substrates having
dened structural diﬀerences, versus log Ki values, for a series of
inhibitors having the analogous structural changes, which show
linear correlations having a slope of unity. Furthermore, log Km
versus log Ki are not correlated for TS analogues but do correlate
for substrate analogues.52
Previous studies showed that NAG-thiazoline analogues are TS
analogues despite their obvious resemblance to the oxazoline
intermediate, perhaps due to the longer C–S bonds altering the
thiazoline ring to resemble a late TS.51Given the greater than 100-
fold increase in potency we observe for the 20-aminothiazoline
inhibitors over their thiazoline counterparts and their structural
resemblance to the oxazoline intermediate found along the
reaction coordinate of hOGA, we wanted to assess whether
incorporation of the 20-amino group benetted binding through
serendipitous interactions, or whether the presence of the charge
included in this class of inhibitors alsomade them TS analogues.
We therefore turned to using the Bartlett LFER approach. With
the series of inhibitors in hand we synthesized a series of uo-
rogenic 4-methylumbelliferyl 2-deoxy-2-urea-b-D-glucopyranoside
substrates (18a–e, Scheme 2) bearing N-alkyl substituents on the
terminal urea nitrogen that correspond to those alkyl groups
present on the series of 20-aminothiazoline inhibitors (11a, 15a,
15c–e). We started from 4-methylumbelliferyl 2-amino-2-deoxy-b-
D-glucopyranoside hydrochloride (16) as a common
Fig. 4 A representative example for 13C-NMR determination of the
pKa value for ThiamEt-G (15c) with chemical shifts of the 2
0-C of the
thiazoline ring resonances (D ppm) for compounds 15c as a function of
the fractional protonation (n) of the reference compound, 3-nitro-
phenol (pKa of 8.42). The solid line is the best non-linear least squares
ﬁt to eqn (S1) (ESI†).
Fig. 5 Acid dissociation of the 20-aminothiazolium protonation state
of 20-aminothiazoline inhibitors 15c and 15f–h and the linear free
energy relationship (LFER) analysis between the pKa and log Ki. Of
these inhibitors shows a negative correlation of 1.12  0.09.
This journal is © The Royal Society of Chemistry 2016 Chem. Sci., 2016, 7, 3742–3750 | 3747
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intermediate.54 Per-O-acetylated urea substrates 17a–e were
prepared by reacting 16 with the appropriate alkylisocyanate in
the presence of triethylamine, followed by Zemplen de-O-acety-
lation. With this series of substrates (18a–e) in hand we deter-
mined the kcat/Km values governing their hOGA catalyzed
hydrolysis (ESI Table S1†). Plotting these data to assess TS
analogy, we observe (Fig. 6) a clear correlation (R2 ¼ 0.9950) with
a slope of 1.08  0.04 between log Ki values for the inhibitors
versus the log Km/kcat values for the corresponding series of urea
substrates (Fig. 6A). In contrast, we nd no correlation between
log Ki values for the inhibitors and log Km values for the series of
substrates (Fig. 6B). These results indicate the 20-aminothiazoline
inhibitors are TS analogues for the hOGA catalyzed hydrolysis of
urea substrates.
We recognized that our observations showed 20-amino-
thiazoline inhibitors are TS analogues for the hOGA-catalyzed
hydrolysis of unnatural urea substrates (18a–e), however, we
were curious as to whether these inhibitors would also be TS
analogues for the hOGA-catalyzed hydrolysis of the more
natural N-acyl substrates. To address this question, we exam-
ined the correlation between log Ki values for the same series of
20-aminothiazoline inhibitors and the series of N-acyl substrates
(Fig. 6C) having the analogous structural changes for which
kcat/Km values are reported (Fig. 6D).
51 We nd a fair correlation
(R2 ¼ 0.9768) with a slope of 2.3  0.3. For this analysis we
excluded the 2-aminothiazoline (11a) because of its unexpect-
edly poor inhibition of hOGA (Table 1).
Notably, previous studies have shown kcat and kcat/Km values
for the OGA-catalyzed hydrolysis of aryl 2-acetamido-2-deoxy-
glucopyranosides, including 19a, vary in according to the pKa
value of the phenolic leaving group.55 Additionally, such
substrates bearing diﬀerent sized N-acyl groups, including 19a–d
(ref. 51) coupled with the large a–D(V)-KIE (kH/kD ¼ 1.14  0.02)
value observed for the OGA-catalyzed hydrolysis of p-nitrophenol
2-acetamido-2-deoxy-glucopyranoside55 all support kcat and kcat/
Km values reect a chemical step being rate limiting for human
OGA, which supports the validity of this TS analogy study.
The steep slope observed for this series of 2-acyl substrates in
correlation with the aminothiazoline inhibitors is surprising.
Scheme 2 Synthesis of 4-methylumbelliferyl ﬂuorogenic substrates
18a–e. (a) R-NCO, NEt3, CH3CN; (b) (i) NaOMe, MeOH; (ii) Dowex
50-H+.
Fig. 6 Analysis of transition state analogy for hOGA 20-aminothiazoline inhibitors (11a, 15a, 15c–e) and urea (18a–e) and acyl (19a–e) substrates.
(A) The correlation between log Km/kcat of substrates 18a–e and log Ki of inhibitors 11a, 15a and 15c–e (m ¼ 1.08  0.04, R
2 ¼ 0.9950). (B) The
correlation between the log Km of substrates 18a–e and log Ki of inhibitors 11a, 15a, 15c–e. (C) The correlation between the log Km/kcat of
substrates 19a–d and log Ki of inhibitors 15a and 15c–e (m¼ 2.31 0.25, R
2¼ 0.9768). (D) Substrates 19a–d synthesized byWhitworth et al.51 (E)
Transition state for the hOGA catalyzed hydrolysis of substrates 19a–d likely involves transfer of the amidic proton. (F) Transition state for the
hOGA catalyzed hydrolysis of substrates 18a–e likely involves no transfer of the amidic proton.
3748 | Chem. Sci., 2016, 7, 3742–3750 This journal is © The Royal Society of Chemistry 2016
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However, slopes other than unity in Bartlett LFER plots are pre-
cedented though not oen rationalized.56 Here, we interpret this
steep slope as indicating that the TS for the hOGA catalyzed
hydrolysis of N-acyl substrates bears less positive charge in the
forming oxazoline ring system. This may arise because the amide
proton is in ight in the TS, as compared to the N-urea substrates
(Fig. 6E and F), which are expected to bemore basic and therefore
likely lead to the formation of 20-amino-oxazolinium ion inter-
mediates that retain their proton. Accordingly, the TS leading to
such aminooxazolinium ion intermediates is expected to have
more positive charge than the corresponding transition state
leading to the oxazoline intermediate (Fig. 6E and F). In keeping
with this proposal, it is notable that site-directed deletion of the
side chain of Asp174, which is the catalytic general acid/base
catalytic residue that interacts with the acetamido group of the
substrate, leads to a similar drop of between 150 to 750-fold in
second order rate constant33 as seen on going from N-acyl to N-
urea substrates (250-fold). Accordingly, these data indicate that
20-aminothiazoline inhibitors are TS analogues for hOGA, by
virtue of both their shape and general charge distribution.
However, the steep slope observed for the LFER between log Km/
kcat values observed for N-acyl substrates and the log Ki values
seen for the 20-aminothiazoline inhibitors suggests that this
feature lends improved binding over the corresponding partial
charge that likely develops for the TS found for the hOGA cata-
lyzed processing of natural N-acyl-containing substrates. These
data support a catalytic mechanism in which residue D174 of
hOGA acts as a general acid/base catalytic residue rather than
simply stabilizing an oxazolinium ion intermediate as proposed
for GH20 b-hexosaminidases.57
Conclusion
In summary, we describe a series of aminothiazoline inhibitors
for human OGA having picomolar and low nanomolar Ki values.
The great potency of this inhibitor family is in large part attrib-
utable to their pKa values since a clear correlation was observed
between the pKa and log Ki of a series of these compounds.
Structures of these inhibitors in complex with BtOGA reveal the
molecular basis for the trends in observed inhibitor potencies
and selectivities. Using quantitative methods we nd that these
20-aminothiazoline inhibitors are tight-binding TS analogues for
hOGA. These inhibitors benet from their formal positive charge
at physiological pH, harnessing favorable interactions that are
only partly realized within the transition state for the natural 2-
acyl-containing substrates. These observations should permit the
design of more potent and selective inhibitors, not only in this
class of inhibitor but also using other inhibitor scaﬀolds. Finally,
the great potencies and selectivities of these inhibitors reveal
a series of useful tool compounds that can be used tomanipulate
hOGA activity in vivo.
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